Fulcrum Therapeutics, Inc. SEC filings FULC

Fulcrum Therapeutics, Inc. has 520 filings in SEC EDGAR's recent list, going back to Jul 25, 2016. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 30, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 17, 2026 (material agreement, unregistered share sale, change in control, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.

Fulcrum Therapeutics, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 30, 2026 Dec 31, 2025
10-K Annual report Feb 24, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 30, 2025 Dec 31, 2024
10-K Annual report Feb 25, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 19, 2024 Dec 31, 2023
10-K Annual report Feb 27, 2024 Dec 31, 2023
10-K/A Amended annual report Jun 26, 2023 Dec 31, 2022
10-K/A Amended annual report Jun 26, 2023 Dec 31, 2021
10-K/A Amended annual report Jun 23, 2023 Dec 31, 2020
ARS Annual report to shareholders Apr 28, 2023 Dec 31, 2022
10-K Annual report Mar 9, 2023 Dec 31, 2022
10-K Annual report Mar 3, 2022 Dec 31, 2021
10-K Annual report Mar 4, 2021 Dec 31, 2020
10-K Annual report Mar 5, 2020 Dec 31, 2019

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
FULC (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1680581

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.